Literature DB >> 9698021

Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.

L Bennet1, H Odeberg.   

Abstract

OBJECTIVE: Inherited resistance to activated protein C (APC resistance), which is caused by a single point mutation in the factor V gene, is a frequent risk factor for venous thromboembolism. The aim of this study was to determine the prevalence of APC resistance and other coagulation disorders in fertile women with venous thromboembolism and also the risk factors these women had been exposed to in connection with thromboembolic events.
DESIGN: A retrospective, case-control study of 36 month duration.
SETTING: The study was carried out at Blekinge Hospital, Karlskrona, Sweden.
SUBJECTS: The study population comprised 27 fertile women age 16-47 years with thromboembolic complications, referred to the department of Internal Medicine at Blekinge Hospital in Karlskrona during a 36-month period.
RESULTS: APC resistance was found in 10 out of 27 women. APC resistance was associated with treatment with oral contraceptives in five out of six women and with pregnancy in one of seven women. All women with resistance to APC developed venous thrombosis in association with a predisposing situation (risk situation) such as surgery, trauma, immobilization, pregnancy, inflammatory state or the use of oral contraceptives. Amongst women not resistant to APC, all but one developed thrombosis in connection with a risk situation.
CONCLUSION: APC resistance was found to be highly prevalent amongst fertile women with a history of thromboembolic complication occurring during their use of oral contraceptives.

Entities:  

Keywords:  Biology; Blood Coagulation Effects; Contraception; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Methods--side effects; Desogestrel--pharmacodynamics; Developed Countries; Diseases; Embolism; Europe; Family Planning; Genetics; Hematological Effects; Hemic System; Northern Europe; Oral Contraceptives, Combined--side effects; Oral Contraceptives--side effects; Physiology; Research Methodology; Research Report; Retrospective Studies; Risk Factors; Scandinavia; Studies; Sweden; Thromboembolism; Vascular Diseases

Mesh:

Substances:

Year:  1998        PMID: 9698021     DOI: 10.1046/j.1365-2796.1998.00310.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  4 in total

1.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.

Authors:  J M Kemmeren; A Algra; D E Grobbee
Journal:  BMJ       Date:  2001-07-21

Review 2.  Cardiovascular events associated with different combined oral contraceptives: a review of current data.

Authors:  P Hannaford
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 3.  Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

Authors:  Lamberto Manzoli; Corrado De Vito; Carolina Marzuillo; Antonio Boccia; Paolo Villari
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

Review 4.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.